Dyne Therapeutics, Inc. Lawsuit Submission Form

First Name

Last Name

Phone

Street Address

City

State

Zip

Shares Owned

Purchase Date

Estimated Loss

Stock Fraud Law Center does not share your information with others. There is no cost or obligation for you to submit.

Investigation Details

Dyne issued a press release on September 3, 2024, “announc[ing] new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping demonstrating unprecedented dystrophin expression and functional improvement in multiple cohorts.” However, in a separate press release on that same day, Dyne announced that the Company’s chief medical officer, chief operating officer, and chief business officer were “step[ping] down from their roles”.

Following this news, Dyne’s stock price fell over 30% on September 3, 2024.

Active Cases

Ticker Symbol	Company Name	Join Deadline	Join
WOLF	Wolfspeed, Inc.	January 17, 2025	Join
SUI	Sun Communities, Inc.	February 10, 2025	Join
SAVA	Cassava Sciences, Inc.	February 10, 2025	Join
APLT	Applied Therapeutics, Inc.	February 18, 2025	Join
BIOA	BioAge Labs, Inc.	March 10, 2025	Join
PCRX	Pacira BioSciences, Inc.	March 14, 2025	Join

Dyne Therapeutics, Inc.

DYN

Dyne Therapeutics, Inc. Form

Active Cases